Authors: Panagiotis Georgoulias Varvara Valotassiou Ioannis Tsougos
Publish Date: 2008/11/05
Volume: 36, Issue: 1, Pages: 160-161
Abstract
We read with great interest the article by Ergün et al published in the August 2008 issue concerning the use of metamizol during 99mTcsestamibi myocardial perfusion scintigraphy MPS for the detection of perfusion reversibility 1 The authors performed 99mTcsestamibi MPS at stress at rest and at rest after the oral administration of 1 g metamizol in 21 patients 14 males 7 females age range 46–74 years mean age 57 years who had partially reversible or irreversible perfusion defects on their stressrest sestamibi scintigram and no history of myocardial infarction Metamizolrest MPS displayed the defect reversibility better than rest MPS defect reversibility was better delineated on metamizolrest MPS in 33 segments while 8 out of 14 fixed perfusion defects on stressrest MPS were shown better on metamizolrest MPS Moreover calculating sestamibi uptake ratios metamizolinduced sestamibi uptake was significantly higher p 0001 than stress/baseline rest
Keywords: